Friday, July 10, 2026

Drug profile · INN

dydrogesterone

dydrogesterone (GYNOREST) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — dydrogesterone
US status
approved
Class
Route
ORAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

dydrogesterone (GYNOREST) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN dydrogesterone
Brand GYNOREST
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route ORAL
Formulation TABLET

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Dydrogesterone 30 mg Phase 3 · Abbott Pathology · Female Infertility
  2. dydrogesterone Phase 3 · Hospital Authority · Preterm Delivery

Related & competitor drugs

  1. desogestrel Progesterone receptor agonist
  2. medroxyprogesterone acetate Progesterone receptor agonist
  3. megestrol acetate Progesterone receptor agonist
  4. norethindrone Progesterone receptor agonist
  5. norethindrone acetate Progesterone receptor agonist
  6. progesterone Progesterone receptor agonist

Frequently asked questions

What is dydrogesterone?

dydrogesterone (GYNOREST) is a progesterone receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for dydrogesterone?

GYNOREST is a marketed brand name for dydrogesterone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dydrogesterone?

dydrogesterone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.